EDITORIAL
Published on 08 Aug 2022
Editorial: Harnessing chemotherapy resistance and development of novel therapeutic strategies for acute leukemia with KMT2A (MLL)-gene rearrangements
doi 10.3389/fphar.2022.977741
- 1,449 views
- 1 citation
- Frontiers in Pharmacology
- Pharmacology of Anti-Cancer Drugs
- Research Topics
- Harnessing Chemotherapy Resistance and development of Novel Therapeutic strategies for Acute Leukemia with KMT2A (MLL)-gene rearrangements
Harnessing Chemotherapy Resistance and development of Novel Therapeutic strategies for Acute Leukemia with KMT2A (MLL)-gene rearrangements
8,431
Total downloads
31k
Total views and downloads
Articles
ORIGINAL RESEARCH
Published on 06 Jun 2022
Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
doi 10.3389/fphar.2022.749472
- 10,212 views
- 13 citations
BRIEF RESEARCH REPORT
Published on 23 May 2022
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
doi 10.3389/fonc.2022.863329
- 2,854 views
- 12 citations
ORIGINAL RESEARCH
Published on 27 Jan 2022
Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia
doi 10.3389/fphar.2021.820191
- 3,882 views
- 9 citations
BRIEF RESEARCH REPORT
Published on 20 Jan 2022
Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia
doi 10.3389/fonc.2021.779859
- 2,382 views
- 4 citations
REVIEW
Published on 14 Sep 2021
Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements
doi 10.3389/fphar.2021.741413
- 7,081 views
- 14 citations
Published in
Frontiers in Pharmacology
Pharmacology of Anti-Cancer Drugs
Participating Journals
Frontiers in Oncology
- 3.3 impact factor
- 6.9 citescore